Prevalence of high-risk HPV types in women with cervical cancer in Eastern Uganda

Ismail Abiola Adebayo

Abstract


Infection of the cervix with human papillomavirus (HPV) is the main cause of intraepithelial neoplasm (CIN) and cervical carcinoma. Accurate identification and typing of these viruses might detect patients with different risk of cervical malignancy. Eighty-three cervical swabs were obtained from the regional referral hospitals of Mbale, Tororo, Butalejja, and Soroti between 2017 and 2019. DNA-Sorb-A DNA extraction kits were used, followed by sensitive HPV Real-Time PCR for genotyping high-risk HPV types.  High-risk HPV genotypes were identified using HPV High-Risk Screen Real-TM Quant 2x kit, an in vitro Real-Time amplification test for the quantitative identification of 12 high-risk human papillomavirus (genotypes16,18,31,33,35,39,45,51,52, 56,58,59). This procedure utilizes probes targeting regions of the HPV group A9 (16, 31, 33, 35, 52, 58), HPV group A7 (18, 39, 45, 59), HPV group A5-A6 (51, 56), as well as the human β-globin gene as an internal control to screen for isolated DNA.  Out of the 83 endocervical uterine swabs, 51 tested positive for HPV DNA. Different HPV genotypes were detectable in 49 incidences: HPV 16, 18, 31, 33, 45 and 52. They manifested as single infections in 46/51 patients (90.2%) and in 3/51 patients (5.9%) as multiple infections. HPV genotypes 16 or 18 contributed to 56.9% (29/51) of the single-infections in the study. The findings of this research affirm the involvement of HPV 16 and 18 in cervical intraepithelial neoplasm and cervical carcinoma pathogenesis in low-income setups. The findings show that the presently available HPV 16 and 18 vaccines might help to deter the significant portion of cervical cancer malignancies in Uganda


Keywords


Human papillomavirus; Cervical Intraepithelial Neoplasia; High-grade squamous intraepithelial lesion; Low-grade squamous intraepithelial lesion; Oral contraceptives; and Carcinoma in situ

Full Text:

PDF

References


Odida M, Sanjosé S De, Quint W, Bosch XF, Klaustermeier J, Weiderpass E. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis. 2008;7(24):1–7.

Tawe L, Grover S. MethodsX Molecular detection of human papillomavirus ( HPV ) in highly fragmented DNA from cervical cancer biopsies using double-nested PCR. MethodsX. 2018;5(2018):569–78.

Thapa N, Maharjan M, Shrestha G, Maharjan N, Petrini MA, Zuo N, et al. Prevalence and type-specific distribution of human papillomavirus infection among women in mid-western rural, Nepal- A population-based study. BMC Infect Dis. 2018;18(1).

Ghorab AE-MMI, Mohamed MAE-H, Eid SMM, Saleh MMA, Semary SE-DSO. Detection Of Human Papillomavirus Genotypes In Cancer Cervix Patients : Damietta Governorate , Egypt By. Al-Azhar Med J. 2019;48(4):407–20.

Tawe L, MacDuffie E, Narasimhamurthy M, Wang Q, Gaseitsiwe S, Moyo S, et al. Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana. Int J Cancer. 2020;146(6):1667–73.

Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst. 1995;87(11):796–802.

Wabinga HR, Nambooze S, Amulen PM, Okello C, Mbus L, Parkin DM. Trends in the incidence of cancer in Kampala, Uganda 1991-2010. Int J Cancer. 2014;135(2):432–9.

Denny L, Prendiville W. International Journal of Gynecology and Obstetrics Cancer of the cervix : Early detection and cost-effective solutions. Int J Gynecol Obstet. 2015;131:S28–32.

Bateman AC, Katundu K, Polepole P, Shibemba A, Mwanahamuntu M, Dittmer DP, et al. Identification of human papillomaviruses from formalin-fixed, paraffin-embedded pre-cancer and invasive cervical cancer specimens in Zambia: A cross-sectional study. Virol J. 2015;12(1).

Nejo YT, Olaleye DO, Odaibo GN. Molecular characterisation of genital human papillomavirus among women in Southwestern, Nigeria. PLoS One. 2019;14(11):1–19.

Orozco-Colín A, Carrillo-García A, Méndez-Tenorio A, Ponce-de-León S, Mohar A, Maldonado-Rodríguez R, et al. Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology. Int J Infect Dis. 2010;14(12):1082–7.

Eliscu A. Human papillomavirus and HPV vaccines. Pediatr Rev. 2017;38(9):443–5.

Yin F, Wang Y, Chen N, Jiang D, Qiu Y, Wang Y, et al. A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model. Papillomavirus Res. 2017;3(February):85–90.

A. Melnick L. Sheng MC. HHS Public Access. Physiol Behav. 2016;176(1):100–106.

Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015;372(8):711–23.

Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, et al. Ce Pt Cr Ipt Us Cr. 2015;1–9.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.

Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 2007;7(1):11–22.

Rad A, Sørbye SW, Dreyer G, Hovland S, Falang BM, Louw M, et al. HPV types in cervical cancer tissue in South Africa: A head-to-head comparison by mRNA and DNA tests. Medicine (Baltimore). 2017;96(47):e8752.

Banura C, Franceschi S, Van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, et al. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer. 2008;123(9):2180–7.

Menon S, Wusiman A, Boily MC, Kariisa M, Mabeya H, Luchters S, et al. Epidemiology of HPV Genotypes among HIV Positive Women in Kenya : A Systematic Review and Meta-Analysis. 2016;

Bekele A, Baay M, Mekonnen Z, Suleman S, Chatterjee S. Human papillomavirus type distribution among women with cervical pathology - A study over 4 years at Jimma Hospital, southwest Ethiopia. Trop Med Int Heal. 2010;15(8):890–3.

Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer. 2011;6(1):11.

Haghshenas M, Golini-Moghaddam T, Rafiei A, Emadeian O, Shykhpour A, Ashrafi GH. Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: A population-based study. Infect Agent Cancer. 2013;8(1):2–7.

Rantshabeng P, Kasvosve I, Ndlovu A, Gaseitsiwe S, Moyo S. Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. PLoS One. 2019;14(1):1–9.

Hopenhayn C, Christian A, Christian WJ, Watson M, Unger ER, Lynch CF, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 us cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014;18(2):182–9.

Chinchai T, Chansaenroj J, Swangvaree S, Junyangdikul P, Poovorawan Y. Prevalence of human papillomavirus genotypes in cervical cancer. Int J Gynecol Cancer. 2012;22(6):1063–8.

Howitt BE, Herfs M, Tomoka T, Kamiza S, Gheit T, Tommasino M, et al. Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women. J Glob Oncol. 2017;3(3):227–34.

Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer. 2014;134(6):1389–98.

Grau LE, Pham T, Leary TO, Rosner J. Cr Ip T Ce Pt E Us Cr Ip T Pt Us. J Infect Dis. 2016;8(2016):1–28.

Mahmoodi P, Motamedi H, Seyfi Abad Shapouri MR, Bahrami Shehni M, Kargar M. Molecular detection and typing of human papillomaviruses in paraffin-embedded cervical cancer and pre-cancer tissue specimens. Int J Cancer Manag. 2016;9(1):13–6.

Romero-Pastrana F. Detection and Typing of Human Papilloma Virus by Multiplex PCR with Type-Specific Primers. ISRN Microbiol. 2012;2012:1–5.

Castellsagué X, Klaustermeier JE, Carrilho C, Albero G, Sacarlal J, Quint W, et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. Int J Cancer. 2008;122(8):1901–4.

Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Heal. 2016;4(7):e453–63.

Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination - Review of Current Perspectives. J Oncol. 2019;2019.

Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.

Snijders PJF, Heideman DAM, Meijer CJLM. Methods for HPV detection in exfoliated cell and tissue specimens. Apmis. 2010;118(6–7):520–8.

Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, et al. Detection of HPV DNA in paraffin-embedded cervical samples: A comparison of four genotyping methods. BMC Infect Dis. 2015;15(1):1–11.

Kabir A, Bukar M, Nggada HA, Rann HB, Gidado A, Musa AB. Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria. Pan Afr Med J. 2019;33(2019):1–11.

Tornesello ML, Cassese R, de Rosa N, Buonaguro L, Masucci

A, Vallefuoco G, et al. High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy. Apmis. 2011;119(10):701–9.

Denny L, Mbatani N, Adams T, Van Wijk L, Behrens C, Tam T, et al. Performance of an Human Papillomavirus Test in Samples from Women with Histopathologically Confirmed Invasive Cervical Cancer. J Low Genit Tract Dis. 2016;20(3):52–3.

Castellsagué X, Diaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303–15.

DeVuyst H. NIH Public Access. PMC. 2012;23(05):1–7.

Alice R, Mahoukèdè T, Patricia S, Marie I, Traore A, Karim A, et al. Oncogenic human papillomavirus infection and genotypes characterization among sexually active women in Tenkodogo at Burkina Faso , West Africa. 2018;6(May):22–6.

Bosch FX, Marcel V, Deacon J, Santamaria M, Chongsuvivatwong V, Meijer CJLM, et al. Risk Factors for Cervical Cancer in Thailand : a Case – Control Study Saibua Chichareon , Rolando Herrero , Nubia Munoz , from infection with HPV to high-grade regard to cervical cancer risk factors . ated cells or frozen biopsy specimens Results The m. Cancer. 1998;90(1).

De Almeida LM, Martins LFL, Pontes VB, Corrêa FM, Montenegro RC, Pinto LC, et al. Human Papillomavirus Genotype Distribution among Cervical Cancer Patients prior to Brazilian National HPV Immunization Program. J Environ Public Health. 2017;2017.

Thapa N, Maharjan M, Shrestha G, Maharjan N, Petrini MA, Zuo N, et al. Prevalence and type-specific distribution of human papillomavirus infection among women in mid-western rural, Nepal- A population-based study. BMC Infect Dis. 2018;18(1):1–9.

Zhong T, Zhou J, Hu R, Fan X, Xie X, Liu Z, et al. Journal of Infection and Public Health Prevalence of human papillomavirus infection among 71 , 435 women in Jiangxi Province , China. 2017;10:783–8.

Chaolki N, Xavier Bosch F, Muñoz N, Chris JLMM, El Gueddari B, El Ghazi A, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer. 1998;75(4):546–54.

Santos C, Muoz N, Klug S, Almonte M, Guerrero I, Alvarez M, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 2001;85(7):966–71.

Herrero R, González P, Markowitz LE, Rica C. Series HPV and cancer 1 Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16(2015):206–16.

Pista A, De Oliveira CF, Cunha MJ, Paixao MT, Real O.

Prevalence of human papillomavirus infection in women in Portugal the CLEOPATRE Portugal study. Int J Gynecol Cancer. 2011;21(6):1150–8.

Kulhan M, Kulhan NG, Seven Y, Nayki UA. Estimation of the prevalence and distribution of HPV genotypes and identification of related risk factors among Turkish women. 2016;

Salazar KL, Zhou HS, Xu J, Peterson LE, Schwartz MR, Mody DR, et al. Multiple Human Papilloma Virus Infections and Their Impact on the Development of High-Risk Cervical Lesions. Acta Cytol. 2015;59(5):391–8.

Odida M, Sanjosé S De, Quint W, Bosch XF, Klaustermeier J, Weiderpass E. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. 2008;7:1–7.

Kolawole O, Ogah J, Alabi O, Suleiman M, Amuda O, Kolawole

F. Utilization of human papillomavirus dna detection for cervical cancer screening in women presenting with abnormal cytology in

Lokoja, Nigeria. Jundishapur J Microbiol. 2015;8(10):8–13.

Cook LS, Koutsky LA, Holmes KK. Circumcision and sexually transmitted diseases. Am J Public Health. 1994;84(2):197–201.

Eilu E, Aliero AA, Odoki M, Tibyangye J, Akinola SA, Ntulume I, et al. Prevalence of cervical intraepithelial neoplasia and its associated factors among women attending healthcare services in Eastern Uganda. 2020;12(June):1–12.

Wideroff L, Schiffman M, Haderer P, Armstrong A, Greer CE, Manos MM, et al. Particles in a Case-Control Study of Cervical Squamous Intraepithelial Lesions. J Infect Dis. 1999;180(1999):1424–8.

Kibira Simon P.S, Elizabeth Nansubuga NMT. HIV Status in Uganda. 2013;(August).

Kagaayi J, Kong X, Kigozi G, Ssekubugu R, Kigozi G, Nalugoda F, et al. Self-selection of male circumcision clients and behaviors following circumcision in a service program in Uganda. Aids. 2016;30(13):2125–9.

Muñoz N, Xavier Bosch F, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.

Bertram CC. Evidence for practice: oral contraception and risk of cervical cancer. J Am Acad Nurse Pract. 2004;16(10):455–61.

Squamous L, Moscicki A, Hills N, Shiboski S, Powell K, Jay N, et al. Risks for Incident Human Papillomavirus in Young Females. Jama. 2012;285(23):2995–3002.

Schmauz R, Okong P, de Villers E-M, Dennin R, Brade L, Lwanga S, et al. High-Incidence Area in Tropical Africa. Int J cancer. 1989;43:805–9.

Moodley JR, Hoffman M, Carrara H, Allan BR, Cooper DD, Rosenberg L, et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: A case-control study. BMC Cancer. 2006;6:1–6.

Gichangi PB, Bwayo J, Estambale B, De Vuyst H, Ojwang S, Rogo K, et al. Impact of HIV infection on invasive cervical cancer in Kenyan women. Aids. 2003;17(13):1963–8.

Meulen J Ter, Eberhardt HC, Luande J, Mgaya HN, Chang‐Claude J, Mtiro H, et al. Human papillomavirus (HPV) infection, hiv infection and cervical cancer in Tanzania, East Africa. Int J Cancer. 1992;51(4):515–21.

Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y, et al. HPV genotype prevalence and distribution during 2009-2018 in Xinjiang, China: Baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19(1):1–14




Copyright (c) 2021 Journal of Biomedical and Clinical Sciences (JBCS)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

 

Flag Counter           

                     

                                              Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
                                            Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.